Jefferies 2016 Healthcare Conference. Howard Robin President & Chief Executive Officer
|
|
- Thomasina Harris
- 6 years ago
- Views:
Transcription
1 Jefferies 2016 Healthcare Conference Howard Robin President & Chief Executive Officer June 8, 2016
2 This presentation includes forward-looking statements regarding Nektar s technology platform, drug candidates, clinical and regulatory objectives, future availability of clinical trial data, market opportunity estimates, and royalty and milestone payment potential. Actual results could differ materially and these statements are subject to important risks detailed in Nektar's filings with the SEC including the Form 10-K filed on February 29, Nektar undertakes no obligation to update forward-looking statements as a result of new information or otherwise.
3 Nektar Therapeutics: A Broad Portfolio and Pipeline Two Commercial Products Partnered Portfolio Could Generate >$750M/year Royalty Income Five Mid to Late Stage Clinical Candidates (Biogen) Amikacin Inhale Cipro DPI Fovista PEGPH20 Dapirolizumab pegol Three Clinical Drug Candidates Nektar-Owned Drug Candidates NKTR-181 Abuse-deterrent Opioid NCE NKTR-214 Immuno- Oncology Next IND Filings/Discovery Programs ONZEALD (NKTR-102) Metastatic Breast Cancer with Brain Metastases NKTR-255 Immuno- Oncology NKTR-358 Immunology Multiple Candidates Spanning Immuno-oncology, Immunology and CNS 3
4 The Epidemic of Opioid Abuse and Addiction Existing opioid molecules present an intrinsic abuse and addiction liability Current opioid formulations can be converted back to their rapid-acting form by abusers who seek a euphoric high ~26-36 million people abuse opioids worldwide Deaths from opioid abuse in U.S. have more than tripled in the last 20 years Emergency room visits from opioid overdoses in U.S. have doubled in the last 5 years Oxycodone OxyContin All abuse deterrent opioid formulations are simply pre-cursors to rapid-acting opioids Source: Volkow et. al., NIH NIDA 2014 Senate Caucus on International Narcotics Control, America s Addiction to Opioids: Heroin and Prescription Drug Abuse 4
5 NKTR-181: A Novel Opioid Poised to Transform Treatment of Chronic Pain NKTR-181 properties are inherent to molecule and not a result of a formulation: Slow rate of entry into CNS designed to reduce euphoria and resulting abuse liability Designed to cause less sedation and reduce risk of respiratory depression Antidepressants $1.5B $20 Billion+ Global Chronic Pain Therapy Market Antiepileptics $3.6B NSAIDs/COX-2s $5.9B Opioids $12.6B Targeting C-III or better scheduling Received Fast Track Status from FDA Chronic pain market includes: Chronic back pain Osteoarthritis Fibromyalgia Neuropathic pain Source: 2013 IMS and Decision Resources 5
6 Plasma Concentration Human Studies Demonstrate that NKTR-181 Enters the Brain Slowly Plasma Concentration Oxycodone Plasma to CNS Equilibration 1 NKTR-181 Plasma to CNS Equilibration 2 Pupil Constriction Pupil Constriction 2.9 Hours 11 Minutes Plasma Drug Concentration Pupil Constriction Slow brain entry inherent to molecular structure, and not a result of a formulation approach 6
7 NKTR-181: Phase 2 Human Abuse Liability Trial Drug High Oral solution: NKTR-181 has significantly lower drug high ratings than oxycodone (p < ) Abstract #683 / Poster Board #21: Presented at the 2013 College on Problems of Drug Dependence (CPDD) Annual Meeting, San Diego, CA Time (Hours Post Dose) 7
8 NKTR-181: Phase 3 Efficacy Topline Data in Q First efficacy study ongoing in opioid-naïve patients with chronic low back pain (SUMMIT-07) Topline data expected in Q Pivotal human abuse liability study to start in Q Topline data expected in 1H 2017 Second efficacy study planned in opioid-experienced patients following completion of first efficacy study and HAL study Long-term (52-week) safety study (SUMMIT-LTS) continuing 8
9 ONZEALD : Collaboration with Daiichi Sankyo Europe Topo-I inhibitor targets DNA replication process causing tumor cell death ONZEALD (NKTR-102) doubled overall survival in pre-specified subgroup of patients with breast cancer and brain mets in Phase 3 BEACON trial CHMP granted accelerated review timeline for ONZEALD conditional MAA Collaboration enables potential EU conditional approval and launch as soon as 2017 Confirmatory trial will enable Nektar to file for ONZEALD approval in the U.S. Nektar retains US and ROW rights Economics: Nektar receives $20 million upfront and $10 million for conditional marketing authorization from EMA Nektar receives $25 million for final marketing authorization from EMA with additional $25 million in potential sales milestones Nektar receives 20% royalty on net sales in Europe 9
10 Goal of Immuno-Oncology is to Optimize the Immune System to Fight Cancer 2 NKTR-214 Prime, Proliferate, Activate & Increase Tumor-Infiltrating Lymphocytes (TILs) 3 Generate Tumor Antigen Radiation, Cytotoxics Release Immunosuppression Checkpoint Inhibitors 1 Sustain Immune Activation & Boost Memory 4 10
11 IL-2: A Pathway with Significant Untapped Potential IL-2: The Central Immuno-Stimulatory Cytokine IL-2 is the master growth factor for T-cells and Natural Killer (NK) cells It was discovered that activation of IL-2 pathway itself has opposing effects on the immune response rhil-2 protein therapy (aldesleukin) requires high and frequent dosing in ICU which results in severe side effects 11
12 IL-2 Receptor is an Attractive Cancer Target but Has Pleiotropic Opposing Effects IL-2Ra IL-2 IL-2 b CTLs T regs ab CD8+ T-Cells and NK Cells CD4+ Regulatory T-Cells IL-2R IL-2Rb Stimulates Immune Response to Kill Tumor Cells Down-Regulates Proliferation of CD8+ T-cells and Suppresses Immune Response 12
13 NKTR-214: Biasing Action to CD 122, or IL-2R Beta, to Stimulate T-Cell Production NKTR-214 NKTR-214 b CTLs T regs ab CD8+ T-Cells and NK Cells CD4+ Regulatory T-Cells IL-2R IL-2Rb Stimulates Immune Response to Kill Tumor Cells Down-Regulates Proliferation of CD8+ T-cells and Suppresses Immune Response 13
14 T o t a l C D 8 T c e l l s ( % ) T o t a l C D 8 T c e l l s ( % ) T o t a l C D 8 T c e l l s ( % ) NKTR-214 Selectively Grows Tumor-killing T Cells Within the Tumor in B16F10 Mouse Melanoma Model NKTR-214 Single Dose Compared to to a 15-fold Higher Cumulative Dose of Aldesleukin NKTR-214 Single Dose: 400-fold Increase in Ratio of CD8+ Tumor-killing T Cells to T-Reg Cells T o t a l C D 8 T c e l l s ( % ) T o t a l C D 8 / T r e g r a t i o D ady a5 y D a5 y 5 D ady a7 y D a7 y 7 0 D a y 5 D a y 7 D a y 5 D a y 7 V e Vh ei chv l iec hl ei c l e A l da el ds Al el sd ul ek us i nl ke iun k i n N KNT KR NT - 2R K 1- T24 R B16F10 melanoma, C57Bl/6 mice; N=9-12/group NKTR-214 2mg/kg i.v. single-dose; Aldesleukin 3mg/kg i.p. BIDx5 14
15 NKTR-214 Produced Complete Responses In Lewis Lung Carcinoma As Single-Agent T u m o r V o l u m e ( m m 3 ) N K T R Aggressive model of squamous lung carcinoma Therapeutic treatment (not prophylactic) of established tumors D a y s 6 / 1 0 T u m o r - f r e e 60% Complete Response with Single-Agent NKTR-214 LLC lung carcinoma, C57Bl/6 mice NKTR-214, 0.7mg/kg i.v. q9dx3 N=10/group 15
16 NKTR-214 Produced Survival Benefit as a Single-Agent in Osteosarcoma K7M2 syngeneic mouse model of osteosarcoma Lung metastasis pathology Balb/c mice were given K7M2 via IV route. Arrows, NKTR mg/kg dosed IV on Days 1, 10, 19 and monitored for survival 16
17 NKTR-214 Produced Survival Benefit as a Single-Agent in Osteosarcoma K7M2 syngeneic mouse model of osteosarcoma Lung metastasis pathology Only 3 doses of NKTR-214 as a single-agent more than doubled survival NKTR-214 dramatically increased effector cells in metastasized lung tumors Balb/c mice were given K7M2 via IV route. Arrows, NKTR mg/kg dosed IV on Days 1, 10, 19 and monitored for survival 17
18 NKTR-214 Single-Agent Phase 1/2 Clinical Trial at MD Anderson and Yale: Topline Phase 1 Data Expected in 2H 2016 Dose Escalation Identify the recommended Phase 2 dose Safety and tolerability Objective response rate (ORR) Measure biomarkers in blood and tumor Enrolling patients who failed at least 1 prior treatment regimen One Protocol / Continuous Study Establish Phase 2 Dose Potential Expansion Cohorts N ~ up to 60 Expansion Cohort 1 Malignant Melanoma Expansion Cohort 2 Renal Cell Carcinoma Expansion Cohort 3 NSCLC Additional Cohorts Osteosarcoma/Rare Tumors 2H 2016 Q Q
19 Goal of Immuno-Oncology is to Optimize the Immune System to Fight Cancer 2 NKTR-214 Prime, Proliferate, Activate & Increase Tumor-Infiltrating Lymphocytes (TILs) 3 Generate Tumor Antigen Radiation, Cytotoxics Release Immunosuppression Checkpoint Inhibitors 1 Sustain Immune Activation & Boost Memory 4 19
20 NKTR-214: Making Checkpoint Inhibitors Work Better (Anti-CTLA-4 and Anti-PD-1) M e a n T u m o r V o l u m e ( m m 3 ) Colon Carcinoma (CT26) NKTR Anti-CTLA-4 NKTR Anti-PD Vehicle Anti-CTLA-4 NKTR-214 M e a n T u m o r V o l u m e ( m m 3 ) Vehicle Anti-PD-1 NKTR D a y s D a y s CT26 colon carcinoma, Balb/c mice; n=10/group Anti-CTLA-4, 100µg i.p., twice-weekly; Anti-PD-1, 200µg i.p., twice-weekly; NKTR-214, 0.8mg/kg i.v. q9dx3 20
21 NKTR-214: Making Checkpoint Inhibitors Work Better (Anti-CTLA-4 and Anti-PD-1) M e a n T u m o r V o l u m e ( m m 3 ) Colon Carcinoma (CT26) NKTR Anti-CTLA-4 NKTR Anti-PD Vehicle Anti-CTLA-4 NKTR-214 M e a n T u m o r V o l u m e ( m m 3 ) Vehicle Anti-PD-1 NKTR Combination Combination D a y s D a y s CT26 colon carcinoma, Balb/c mice; n=10/group Anti-CTLA-4, 100µg i.p., twice-weekly; Anti-PD-1, 200µg i.p., twice-weekly; NKTR-214, 0.8mg/kg i.v. q9dx3 21
22 M e a n T u m o r V o l u m e ( m m 3 ) Maximal T-cell Expansion and T-Cell Clonality is Associated with Optimal Anti-Tumor Response M e a n T u m o r V o l u m e ( m m 3 ) NKTR apd-1 ImmunoSEQ Data in Model of Colon Carcinoma (in collaboration with Adaptive Biotechnologies) NKTR apd D a y s NKTR actla4 actla4 + apd-1 NKTR actla4 NKTR Vehicle apd-1 actla D a y s AACR 2016; Data from Adaptive Biotechnologies; CT26 colon carcinoma, Balb/c mice; n=10/group Anti-CTLA-4, 100µg i.p., twice-weekly; Anti-PD-1, 200µg i.p., twice-weekly; NKTR-214, 0.8mg/kg i.v. q9dx3 22
23 Goal of Immuno-Oncology is to Optimize the Immune System to Fight Cancer 2 NKTR-214 ONZEALD Topo-I inhibitor Prime, Proliferate, Activate & Increase Tumor-Infiltrating Lymphocytes (TILs) 3 Generate Tumor Antigen Radiation, Cytotoxics Release Immunosuppression Checkpoint Inhibitors 1 NKTR-255 (IL-15) Sustain Immune Activation & Boost Memory 4 23
24 Auto-Immune Disease is Characterized by Imbalance of T-Reg Cells to T-Effector Cells Beneficial effector T cell population Pathological overpopulation of antigen-specific (self-reactive) effector T cells Current auto-immune disease therapies work by suppressing overall immune system function Insufficient T-reg cell population to control the pathological effector T cells Treat symptoms of the overactive immune system Do not address underlying pathology Block both pathological and beneficial effector T cells resulting in infection, bleeding, cancer risks, etc. 24
25 NKTR-358: Growing the Body s Own Population of T-Reg Cells to Treat Auto-Immune Disease Restore balance and normalize T-reg cell and T-effector cell function What if you could grow the body s own population of T-reg cells and directly treat the underlying disease pathology? 25
26 IL-2 Signaling is Required for Regulatory T-Cell Growth, Survival and Function IL-2Ra IL-2 IL-2 b CTLs T regs ab CD8+ T-Cells and NK Cells CD4+ Regulatory T-Cells IL-2R IL-2Rb Stimulates Immune Response to Kill Tumor Cells Tregs Down-Regulate Proliferation of CD8+ T-cells and Suppresses Immune Response 26
27 NKTR-358: Stimulates Growth of the T-Reg Cell Population IL-2Ra NKTR-358 NKTR-358 Selectively Expands T-Reg Cells b CTLs T regs ab CD8+ T-Cells and NK Cells CD4+ Regulatory T-Cells IL-2R IL-2Rb Stimulates Immune Response to Kill Tumor Cells Tregs Down-Regulate Proliferation of CD8+ T-cells and Suppresses Immune Response 27
28 NKTR-358 is Selective for Enhancement of T-Reg Proliferation and Activation in Non-Human Primates Fold Change in Treg and Teff Treg Teff Dosing Single dose NKTR-358 produced greater Treg expansion than repeat low-dose IL-2 In mice, NKTR-358 treatment promotes >30-fold increase in Treg suppressive activity NKTR-358 could be a better approach to treating multiple auto-immune diseases including rheumatoid arthritis, Crohn s disease, psoriasis, lupus, and transplant 1M + 1F cynomolgus monkey per treatment, both agents given at mg/kg single dose SC for NKTR-358 vs QDx5 SC for IL-2. Cell analysis conducted using flow cytometry of peripheral blood T cells 28
29 Key Anticipated Milestones Second Half 2016: Additional European & rest of world country launches for Movantik (Partner AstraZeneca in ROW and ProStrakan in Europe) Topline data from NKTR-214 Phase 1 dose-escalation trial in cancer Completion of second Cipro DPI Phase 3 efficacy trial in bronchiectasis (Partner Bayer) Topline data from Fovista Phase 3 efficacy trial in wet AMD (Partner Ophthotech) Q1 2017: CHMP opinion regarding conditional market authorization for ONZEALD in Europe Topline data from NKTR-181 Phase 3 efficacy trial in chronic pain Topline data from Amikacin Inhale Phase 3 Program in gram-negative pneumonia (Partner Bayer) Submit IND filing for NKTR-358 Potential European approval and launch for ADYNOVATE in hemophilia A (Partner Baxalta) 29
Jefferies 2017 Global Healthcare Conference. Stephen Doberstein, Ph.D. Senior Vice President & Chief Scientific Officer
Jefferies 2017 Global Healthcare Conference Stephen Doberstein, Ph.D. Senior Vice President & Chief Scientific Officer June 7, 2017 This presentation includes forward-looking statements regarding Nektar
More informationPiper Jaffray 29 th Annual Healthcare Conference
Piper Jaffray 29 th Annual Healthcare Conference Jonathan Zalevsky, Ph.D. Senior Vice President, Research and Chief Scientific Officer November 28, 2017 This presentation includes forward-looking statements
More informationJP Morgan Healthcare Conference. Howard Robin President & CEO January 9, 2018
JP Morgan Healthcare Conference Howard Robin President & CEO January 9, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start
More informationEnhanced Cancer Vaccine Effectiveness with NKTR-214, a CD122-Biased Cytokine
Enhanced Cancer Vaccine Effectiveness with NKTR-214, a CD122-Biased Cytokine Jonathan Zalevsky SVP, Biology and Preclinical Development Nektar Therapeutics SMI Cancer Vaccines, September 2017 Nektar Therapeutics
More informationNKTR-214 plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology
plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology Jonathan Zalevsky SVP, Biology and Preclinical Development Nektar Therapeutics World Preclinical Congress, 2017
More informationEnhanced cancer vaccine effectiveness with NKTR-214, a CD122 biased cytokine
SMi Immuno-Oncology, London Loui Madakamutil, Ph. D Vice President, Head for Discovery Enhanced cancer vaccine effectiveness with NKTR-214, a CD122 biased cytokine Sept 26-27 2018 Nektar Therapeutics San
More informationJefferies 2018 Healthcare Conference. June 6, 2018
Jefferies 2018 Healthcare Conference z June 6, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and conclusion of ongoing
More informationNektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018
Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationNKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity
NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity Peiwen Kuo Scientist, Research Biology Nektar Therapeutics August 31 st, 2018 Emerging
More information2019 ASCO-SITC. Nektar Therapeutics Investor & Analyst Call. March 1, 2019
Nektar Therapeutics Investor & Analyst Call March 1, 2019 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and conclusion of
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationNKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies
NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies Saul Kivimäe Senior Scientist, Research Biology Nektar Therapeutics NK Cell-Based Cancer Immunotherapy, September 26-27,
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationJohn Langowski, Ph.D. Nektar Therapeutics San Francisco, CA USA
NKTR-38: a selective, first-in-class IL-2 pathway agonist which increases number and suppressive function of regulatory T cells for the treatment of immune inflammatory disorders John Langowski, Ph.D.
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationThe Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy
The Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy Supplemental Information to Corporate Presentation February 6, 2018 NASDAQ: GALT www.galectintherapeutics.com 2018 2017 Galectin Therapeutics
More informationONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Companies to develop and commercialize Opdivo (nivolumab), ipilimumab,
More informationCOMPANY OVERVIEW. June CytomX Therapeutics, Inc.
COMPANY OVERVIEW June 2016 2016 CytomX Therapeutics, Inc. Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking
More information37th Annual J.P. Morgan Healthcare Conference. Howard Robin President & CEO January 8, 2019
37th Annual J.P. Morgan Healthcare Conference Howard Robin President & CEO January 8, 2019 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies Healthcare Conference June 2015 Disclosure Notice This presentation may contain projections and other forward-looking statements
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationInovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationJEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018
1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationIdentification of novel immune regulators of tumor growth using highthroughput
Identification of novel immune regulators of tumor growth using highthroughput screening in vivo Tom Brennan 1 Five Prime s Unique Platform Tests Nearly Every Extracellular Protein to Identify Protein
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationCEL-SCI Corporation. NYSE American: CVM
CEL-SCI Corporation NYSE American: CVM Geert Kersten Chief Executive Officer 8229 Boone Boulevard, Suite 802 Vienna, VA 22182, USA Phone: (703) 506-9460 Forward Looking Statements This presentation includes
More informationBAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY
BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY This presentation includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO Forward-Looking Statements This
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationNEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan
NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR
More informationYour Contacts. EMA ODD is an important regulatory milestone for avelumab in metastatic Merkel cell carcinoma (MCC)
Your Contacts News Release Merck KGaA, Darmstadt, Germany Media: Gangolf Schrimpf +49 6151 72 9591 Investor Relations: +49 6151 72 3321 Pfizer Inc., New York, USA Media: Lisa O Neill +44 1737 331536 Investor
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationNOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by
More informationTHE FUTURE OF VACCINES ASCO ANNUAL MEETING JUNE 4, 2016
THE FUTURE OF VACCINES ASCO ANNUAL MEETING JUNE 4, 2016 1 BAVARIAN NORDIC INVESTOR & ANALYST UPDATE & RECEPTION Welcome and Introduction to Bavarian Nordic s Cancer immunotherapy Programs Paul Chaplin,
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationCorporate Overview. June 2017 NASDAQ:FPRX
Corporate Overview June 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationTargeting the Tumor Locally
ARMING THE IMMUNE SYSTEM TO FIGHT CANCER Targeting the Tumor Locally October 2017 NASDAQ:ONCS Cautionary Note Regarding Forward-Looking Statements To the extent statements contained in the following presentations
More informationImmuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies 2016 DISCLOSURE NOTICE This presentation may contain projections and other forward-looking statements regarding future events.
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationMOLOGEN AG Jefferies 2014 London Healthcare Conference
Jefferies 2014 London Healthcare Conference Dr. Matthias Schroff Chief Executive Officer London 20 November 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring
More informationMedia Release. Basel, 26 March 2018
Media Release Basel, 26 March 2018 Phase III IMpower150 study showed Roche s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationUnder the terms of the agreement, AVEO will receive an initial cash payment of $125 million, composed of a $75 million license fee and $50 million in
Astellas Pharma Inc. AVEO Pharmaceuticals Corporate Communications Investor Contact: Astellas Pharma Inc. Monique Allaire AVEO Pharmaceuticals +81(3)-3244-3201 (617) 299-5810 Media Contact: Dan Budwick
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationCytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer
November 26, 2018 CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer VANCOUVER, Washington, Nov. 26, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc.
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationOncoSec Provides 2018 Business Outlook
January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationTitan Pharmaceuticals Overview
Corporate Presentation July 2014 1 Safe Harbor The presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationImmuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
More informationCorporate Overview. June 2018 NASDAQ:FPRX
Corporate Overview June 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationData will be submitted to health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)
Investor Update Basel, 20 November 2017 Phase III IMpower150 study showed Roche s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationTransforming science into medicine
Transforming science into medicine 2 Forward-looking statements This presentation contains forward-looking statements. These statements include words like may, expects, believes, plans, scheduled, and
More information9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO
9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO BERLIN, 13 NOVEMBER, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationEvidence for Systemic Effects Moves PV-10 Toward Further Clinical Trials
PV-10 Moves Forward-1 Evidence for Systemic Effects Moves PV-10 Toward Further Clinical Trials At the same time that current research projects are solidifying and reinforcing the evidence for PV-10 s systemic
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationONCOS-102 in mesothelioma. Dr Magnus Jaderberg Chief Medical Officer Targovax
ONCOS-102 in mesothelioma Dr Magnus Jaderberg Chief Medical Officer Targovax ONCOS CLINICAL DEVELOPMENT STRATEGY 1 2 3 4 Path-to-market Mesothelioma Proof-of-concept CPI refractory Proof-of-concept New
More informationIncyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Print Page Close Window Press Release Incyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs $84.0 million of 2014 second quarter net product revenues from
More informationINTERIM RESULTS AS OF MARCH 31, 2018
INTERIM RESULTS AS OF MARCH 31, 2018 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationCOMPANY PRESENTATION. January 2019
COMPANY PRESENTATION January 2019 1 FORWARD-LOOKING STATEMENT This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationBayer to Present New Data on Advancing Oncology Portfolio. New Preclinical and Early Clinical Data Evaluating Innovative Compounds in Drug Development
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com 105 th Annual Meeting American Association for Cancer Research Bayer to Present
More informationIncyte Corporation. Hervé Hoppenot President & CEO. 34th J.P. Morgan Annual Healthcare Conference January 11, 2016
Incyte Corporation Hervé Hoppenot President & CEO 34th J.P. Morgan Annual Healthcare Conference January 11, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters
More informationThe Tumor Microenvironment Company
The Tumor Microenvironment Company June 2018 Legal Disclaimer This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
More informationImmunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma
PRESS RELEASE IMMUNOCORE LIMITED Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma (Oxford, UK, 16 April 2015) Immunocore Limited, a world-leading
More informationFrédéric Triebel MD, PhD World Immunotherapy Congress Basel, October 30, 2018
Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab Frédéric Triebel MD, PhD World Immunotherapy Congress
More informationBuilding a Premier Oncology Biotech
Corporate Presentation Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO February 2019 Forward-Looking Statements All of the statements in this presentation that are not statements
More information